PAD-LOCK
DEAD

Serial Number

97716190

Owner

Enlaza Therapeutics, Inc.

Attorney

Alyssa M. Worsham

Filing Date

Dec 13, 2022

Add to watchlist:

No watchlists yet
View on USPTO

PAD-LOCK Trademark

Serial Number: 97716190

PAD-LOCK is a trademark filed by Enlaza Therapeutics, Inc. on December 13, 2022. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

Enlaza Therapeutics, Inc. (3 trademarks)

11099 North Torrey Pines Road, Suite 280
La Jolla, CA 92037

Entity Type: 03

Trademark Details

Filing Date

December 13, 2022

Registration Date

Not Registered

Goods & Services

Pharmaceutical products, preparations, and substances for the treatment of cancer; cancer therapeutics, namely, anti-cancer preparations; novel cancer therapies, namely, pharmaceutical preparations and substances for the treatment of cancer and tumors; biological preparations and substances for the treatment, diagnosis, detection, and prevention of cancer; pharmaceutical products consisting of covalent protein biologics; pharmaceutical products, namely, covalent protein drugs; pharmaceuticals products consisting of synthetic biology enabled covalent protein biologics; pharmaceutical products consisting of covalent protein drugs; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals

Chemical products for use in industry and science; reagents for use in scientific apparatus for chemical or biological analysis; reagents for medical research; antibody reagents for scientific purposes; in-vivo diagnostic reagents for scientific or research use; enzymes for scientific use; cell culture media for use in scientific research; active chemical ingredients for use in the manufacture of anti-cancer drugs; laboratory chemicals, namely, an antibody reagent used for the detection of cancerous tumors; antibodies for research use

Research and development in the field of covalent protein biologics; medical and scientific research in the field of cancer treatment and diagnosis; pharmaceutical research and development; research and development of pharmaceuticals and biologicals in the field of cancer therapeutics; research and development in the field of synthetic biology enabled covalent therapeutics and covalent protein drugs; research and development for the purpose of selective covalent modification of proteins; research and development in the field of oncology, namely, development of a biotechnology platform to create covalent protein biologics for treating cancer; research and development in the field of covalent protein drugs, namely, development of a platform technology for identification of small-molecule and biologic therapeutics for treating cancer and targeting tumors; conducting clinical trials for others in the field of cancer therapeutics; biotechnology testing services, namely, synthetic chemistry, recombinant protein production, bioconjugation, testing, and analysis; research and development services in the field of antibody-drug conjugates, T cells, natural killer (NK) cells, and macrophage engaging antibodies; research and development services for the purpose of antibody engineering, namely, custom design and engineering of antibodies

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Jan 9, 2024 MAB2
ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Jan 9, 2024 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Jan 9, 2024 ABN2
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 23, 2023 GNRN
NON-FINAL ACTION E-MAILED
Sep 23, 2023 GNRT
NON-FINAL ACTION WRITTEN
Sep 23, 2023 CNRT
ASSIGNED TO EXAMINER
Sep 16, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 10, 2023 NWOS
NEW APPLICATION ENTERED
Dec 16, 2022 NWAP